Breaking Down SG&A Expenses: Cytokinetics, Incorporated vs Taro Pharmaceutical Industries Ltd.

SG&A Expenses: Cytokinetics vs. Taro Pharmaceuticals

__timestampCytokinetics, IncorporatedTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 20141726800091733000
Thursday, January 1, 20151966700087644000
Friday, January 1, 20162782300092365000
Sunday, January 1, 20173646800085656000
Monday, January 1, 20183128200088196000
Tuesday, January 1, 20193961000089971000
Wednesday, January 1, 20205282000093413000
Friday, January 1, 20219680300091355000
Saturday, January 1, 2022177977000113676000
Sunday, January 1, 2023173612000198366000
Monday, January 1, 2024218935000
Loading chart...

Unlocking the unknown

A Comparative Analysis of SG&A Expenses: Cytokinetics vs. Taro Pharmaceuticals

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Cytokinetics, Incorporated and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Cytokinetics saw a staggering increase in SG&A expenses, peaking at nearly 178% of their 2014 levels by 2022. In contrast, Taro Pharmaceuticals maintained a more stable trajectory, with expenses rising by approximately 116% over the same period. Notably, in 2023, Taro's SG&A expenses surged to 198% of their 2014 figures, surpassing Cytokinetics. This trend highlights Taro's strategic shift towards increased operational spending. The data for 2024 is incomplete, but the existing trends provide valuable insights into the financial maneuvers of these industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025